Terms: = Leukemia AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Treatment
14034 results:
1. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
Xin F; Yu YH; Shen XL; Zhang GX
Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
[TBL] [Abstract] [Full Text] [Related]
2. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract] [Full Text] [Related]
3. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation.
Gregorio C; Spreafico M; D'Amico S; Sauta E; Asti G; Lanino L; Tentori CA; Platzbecker U; Haferlach T; Diez-Campelo M; Fenaux P; Komrokji R; Della Porta MG; Ieva F
JCO Clin Cancer Inform; 2024 May; 8():e2300205. PubMed ID: 38723213
[TBL] [Abstract] [Full Text] [Related]
4. Systematic analysis of mucosal-associated invariant T cells in haematological malignancies.
Bacova B; Cierny J; Nemcekova L; Smetanova/Brozova J; Novak J
Scand J Immunol; 2024 Jun; 99(6):e13364. PubMed ID: 38720521
[TBL] [Abstract] [Full Text] [Related]
5. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
6. [Efficacy of allogeneic hematopoietic stem cell transplantation based on a total body irradiation conditioning treatment regimen for adult acute lymphocytic leukemia].
Xiao QQ; Yu XL; Song XC; Hou YX; Deng L; Li WJ; Zhou F
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):249-256. PubMed ID: 38716596
[No Abstract] [Full Text] [Related]
7. [treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):215-224. PubMed ID: 38716592
[No Abstract] [Full Text] [Related]
8. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract] [Full Text] [Related]
9. Determination of drug-related problems in the hematology service: a prospective interventional study.
Albayrak A; Özbalcı D
BMC Cancer; 2024 May; 24(1):552. PubMed ID: 38698336
[TBL] [Abstract] [Full Text] [Related]
10. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
[TBL] [Abstract] [Full Text] [Related]
11. A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID.
Cesana D; Cicalese MP; Calabria A; Merli P; Caruso R; Volpin M; Rudilosso L; Migliavacca M; Barzaghi F; Fossati C; Gazzo F; Pizzi S; Ciolfi A; Bruselles A; Tucci F; Spinozzi G; Pais G; Benedicenti F; Barcella M; Merelli I; Gallina P; Giannelli S; Dionisio F; Scala S; Casiraghi M; Strocchio L; Vinti L; Pacillo L; Draghi E; Cesana M; Riccardo S; Colantuono C; Six E; Cavazzana M; Carlucci F; Schmidt M; Cancrini C; Ciceri F; Vago L; Cacchiarelli D; Gentner B; Naldini L; Tartaglia M; Montini E; Locatelli F; Aiuti A
Nat Commun; 2024 Apr; 15(1):3662. PubMed ID: 38688902
[TBL] [Abstract] [Full Text] [Related]
12. Testing an Intervention to Improve Health Care Worker Well-Being During the COVID-19 Pandemic: A Cluster Randomized Clinical Trial.
Meredith LS; Ahluwalia S; Chen PG; Dong L; Farmer CM; Bouskill KE; Dalton S; Qureshi N; Blagg T; Timmins G; Schulson LB; Huilgol SS; Han B; Williamson S; Watson P; Schnurr PP; Martineau M; Davis K; Cassells A; Tobin JN; Gidengil C
JAMA Netw Open; 2024 Apr; 7(4):e244192. PubMed ID: 38687482
[TBL] [Abstract] [Full Text] [Related]
13. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
14. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.
Hermans SJF; van Norden Y; Versluis J; Rijneveld AW; van der Holt B; de Weerdt O; Biemond BJ; van de Loosdrecht AA; van der Wagen LE; Bellido M; van Gelder M; van der Velden WJFM; Selleslag D; van Lammeren-Venema D; van der Velden VHJ; de Wreede LC; Postmus D; Pignatti F; Cornelissen JJ
Cancer Med; 2024 May; 13(9):e6756. PubMed ID: 38680089
[TBL] [Abstract] [Full Text] [Related]
15. Mesenchymal stromal/stem cells promote intestinal epithelium regeneration after chemotherapy-induced damage.
Yetkin-Arik B; Jansen SA; Varderidou-Minasian S; Westendorp B; Skarp KP; Altelaar M; Lindemans CA; Lorenowicz MJ
Stem Cell Res Ther; 2024 Apr; 15(1):125. PubMed ID: 38679715
[TBL] [Abstract] [Full Text] [Related]
16. Improved Survival of Patients With Chronic Lymphocytic leukemia Between 1998-2022, Including the Era of Target Therapies With BCL2 and BTK Inhibitors.
Tadmor T; Melamed G; Alapi H; Gazit S; Patalon T; Rokach L
Anticancer Res; 2024 May; 44(5):2109-2115. PubMed ID: 38677726
[TBL] [Abstract] [Full Text] [Related]
17. Evaluation of a machine-learning model based on laboratory parameters for the prediction of acute leukaemia subtypes: a multicentre model development and validation study in France.
Alcazer V; Le Meur G; Roccon M; Barriere S; Le Calvez B; Badaoui B; Spaeth A; Kosmider O; Freynet N; Eveillard M; Croizier C; Chevalier S; Sujobert P
Lancet Digit Health; 2024 May; 6(5):e323-e333. PubMed ID: 38670741
[TBL] [Abstract] [Full Text] [Related]
18. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
[TBL] [Abstract] [Full Text] [Related]
19. Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Serio B; Grimaldi F; Ammirati L; Annunziata M; De Santis G; Perrotta A; De Novellis D; Giudice V; Morini D; Storti G; Califano C; Risitano AM; Pane F; Selleri C
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2044. PubMed ID: 38662362
[TBL] [Abstract] [Full Text] [Related]
20. [The Role of NK Cells in Allogeneic Hematopoietic Stem Cell Micro-Transplantation for Acute Myeloid leukemia].
Liu RY; Yu CL; Qiao JH; Cai B; Sun QY; Wang Y; Liu TQ; Jiang S; Zhang TY; Ai HS; Guo M; Hu KX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):546-555. PubMed ID: 38660865
[TBL] [Abstract] [Full Text] [Related]
[Next]
